Login to Your Account

DBV, Stallergenes in $198M Pact on Birch Pollen Allergy Therapy

By Cormac Sheridan
Staff Writer

Wednesday, October 23, 2013

Shares in DBV Technologies SA gained more than 9 percent Friday on news of a licensing deal on a treatment for birch (Betula verrucosa) pollen allergy with Stallergenes SA, which is worth up to €145 million (US$198 million) in milestone payments, as well as royalties on potential product sales.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription